Globe Life Inc. (GL) SEC Filings & Earnings Calls
EquiReason read 14 Globe Life Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Globe Life Q3 2026 net operating income $4.84/sh vs $4.81/sh prior; net income $4.62/sh vs $4.73/sh; total premium revenue +7% YoY; 1.1M shares repurchased for $185M; FY26 guidance.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 11.9B
- P/E TTM
- 10.3
- Dividend yield
- 0.8%
- 52-week
- —
- Next earnings
- 2 Feb, in 101 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
21 Oct 20268-K · 2.02Globe Life Q3 2026 net operating income $4.84/sh vs $4.81/sh prior; net income $4.62/sh vs $4.73/sh; total premium revenue +7% YoY; 1.1M shares repurchased for $185M; FY26 guidance adjusted to $15.35-$15.65 from prior range due to one-timeearningsopen
Figures in the filing · each found in the filing text
| Net operating income per diluted share · Q3-2026 | $4.84 | +1% y/y |
| Net income per diluted share · Q3-2026 | $4.62 | -2% y/y |
| Total premium revenue growth · Q3-2026 | 7.0% | |
| Book value per share · Q3-2026 | $85.35 | +23% y/y |
| Book value per share excluding AOCI · Q3-2026 | $103.62 | +11% y/y |
| Net operating income as an ROE (ex-AOCI) · 9M-2026 | 15.9% | |
| Shares repurchased · Q3-2026 | 1,100,000 | |
| Share repurchase cost · Q3-2026 | $185M | |
| Weighted average diluted shares outstanding · Q3-2026 | 78,225,000 | -5% y/y |
Guidance
FY26 net operating income per share guidance adjusted to $15.35-$15.65 from prior range (not explicitly stated but implied lower); FY27 net operating income per share estimated $16.10-$17.10, +7.1% at midpoint.
FY26 guidance cut due to two one-time items at United American General Agency; FY27 initial guidance implies 7.1% growth at midpoint.
Risks flagged
FY26 guidance cut due to one-time items at United American General Agency: high-severity claims at Evry and CMS claims processing delay.
“The Company adjusted full-year 2026 earnings guidance to a range of $15.35 to $15.65 due to two items impacting the results at our United American General Agency division... high-severity claims at Evry... and a claims processing delay at the Centers for Medicare and Medicaid Services.” · word for word
5 Aug 202610-QGlobe Life reported strong Q2 2026 results with net income up 10% and diluted EPS up 16% year-over-year.earningsopen
Figures in the filing · each found in the filing text
| Total premium · H1-2026 | $2.57B | +6% y/y |
| Life premium · Life · H1-2026 | $1.71B | +3% y/y |
| Health premium · Health · H1-2026 | $854M | +14% y/y |
| Net income · H1-2026 | $558M | +10% y/y |
| Diluted net income per common share · H1-2026 | $7.04 | +16% y/y |
| Life underwriting margin · Life · H1-2026 | $708M | +5% y/y |
| Health underwriting margin · Health · H1-2026 | $194M | +6% y/y |
| Excess investment income · Investment · H1-2026 | $75M | +6% y/y |
| Net sales · H1-2026 | $484M | +10% y/y |
| Book value per share · 2026-06-30 | $78.18 | +18% y/y |
Risks flagged
Litigation risk from securities class action and derivative suits
“On April 30, 2024, a putative securities class action was filed against Globe Life Inc. and six of its current/former executives and directors... The Consolidated Complaint added four additional executives as defendants and alleges that certain of Globe Life Inc.'s disclosures about financial performance and certain other public statements during the putativ”
Dependence on agent count for growth
“The average producing agent count decreased 5% over the year-ago period driven by lower retention of new agents.” · word for word
Interest rate sensitivity of investment portfolio
“The net unrealized loss position in the fixed-maturity portfolio increased from $1.2 billion at December 31, 2025 to $1.4 billion at June 30, 2026 due to a change in market rates during the period.” · word for word
22 Jul 20268-K · 2.02Globe Life reported Q2 2026 net income $3.65/diluted share (up 20% YoY), net operating income $3.61 (up 10% YoY); raised FY2026 EPS guidance to $15.55-$15.95; strong underwriting margins across divisions; $175M share repurchase.earningsopen
Figures in the filing · each found in the filing text
| Net income per diluted share · Q2-2026 | $3.65 | +20% y/y |
| Net operating income per diluted share · Q2-2026 | $3.61 | +10% y/y |
| Net income · Q2-2026 | $288M | |
| Net operating income · Q2-2026 | $285M | +5% y/y |
| Total premium revenue · Q2-2026 | $1.30B | +7% y/y |
| Life insurance premium revenue · Life insurance · Q2-2026 | $861M | +3% y/y |
| Health insurance premium revenue · Health insurance · Q2-2026 | $437M | +16% y/y |
| Book value per share · Q2-2026 | $78.18 | +18% y/y |
| Book value per share excluding AOCI · Q2-2026 | $100.04 | +11% y/y |
| Net income as an ROE · H1-2026 | 18.4% |
Guidance
FY2026 EPS guidance raised to $15.55-$15.95 from prior midpoint (increase of $0.10 at midpoint)
Raised full-year 2026 EPS guidance by $0.10 at midpoint, reflecting strong operating momentum.
Risks flagged
Legal proceedings expense continues
“Legal proceedings reconciling item of $(0.03) per share, net of tax, in Q2 2026”
Share repurchase reduces share count, but may signal limited organic reinvestment opportunities
“1.1 million shares repurchased for $175 million; weighted average diluted shares outstanding declined from 82.8M to 78.9M YoY”
7 May 202610-QNet Sales $264M (+22% y/y); Net Income $271M (+6% y/y); Net Operating Income $274M (+5% y/y)open
Figures in the filing · each found in the filing text
| Net Sales · Q1-2026 | $264M | +22% y/y |
| Net Income · Q1-2026 | $271M | +6% y/y |
| Net Operating Income · Q1-2026 | $274M | +5% y/y |
| Life Underwriting Margin · Life Insurance · Q1-2026 | $349M | +3% y/y |
| Health Underwriting Margin · Health Insurance · Q1-2026 | $95M | +12% y/y |
| Book Value Per Share · 2026-03-31 | $77.03 | +19% y/y |
| Net Operating Income ROE (ex AOCI) · Q1-2026 | 14.0% |
Risks flagged
Agent retention pressure in American Income
“The average producing agent count decreased 4% over the year-ago period driven by lower retention of new agents.” · word for word
Interest rate sensitivity on investment portfolio
“The net unrealized loss position in the fixed-maturity portfolio increased from $1.2 billion at December 31, 2025 to $1.6 billion at March 31, 2026 due to a change in market rates during the period.” · word for word
22 Apr 20268-K · 2.02Net income per diluted share $3.39 (+13% y/y); Net operating income per diluted share $3.43 (+12% y/y); Book value per share $77.03 (+19% y/y); Guidance: FY2026 guidance raised to $15.40-$15.90 (+$0.35 midpoint)earningsopen
Figures in the filing · each found in the filing text
| Net income per diluted share · Q1-2026 | $3.39 | +13% y/y |
| Net operating income per diluted share · Q1-2026 | $3.43 | +12% y/y |
| Book value per share · Q1-2026 | $77.03 | +19% y/y |
| Book value per share excluding AOCI · Q1-2026 | $98.56 | +12% y/y |
| Life net sales growth · Life · Q1-2026 | 6.0% | |
| Health net sales growth · Health · Q1-2026 | 58.0% |
Guidance
FY2026 guidance raised to $15.40-$15.90 (+$0.35 midpoint)
Strong earnings beat and raised full-year guidance.
Risks flagged
Share repurchase activity reduces share count.
“1.4 million shares repurchased for $203 million.”
19 Mar 2026DEF 14AGlobe Life Inc. filed its 2026 proxy statement (DEF 14A) for the annual shareholder meeting, disclosing executive compensation, governance practices, and proposals for shareholder vote.open
Figures in the filing · each found in the filing text
| Operating EPS · FY2025 | $14.52 | +17% y/y |
| Total net sales · FY2025 | $948M | +13% y/y |
| Book value per share · FY2025 | $74.17 | +19% y/y |
| Average producing agent count · FY2025 | 3.0% | |
| Shareholder returns · FY2025 | $770M | |
| Net income · FY2025 | $1.16B | +8% y/y |
| Total Premium · FY2025 | $4.89B | |
| First-Year Collected Premium · FY2025 | $594M | |
| Book Value + Dividends per Diluted Shares Outstanding (3-year cumulative) · 2023-2025 | $99.35 | |
| Average Net Operating Income ROE (3-year average) · 2023-2025 | 15.3% |
Risks flagged
Cybersecurity risk is a material enterprise risk, but governance and mitigation programs are in place.
“The Board considers information security to be an enterprise-wide risk management issue and oversees material cybersecurity risks through the Audit Committee. ... The Chief Information Security Officer (CISO), who reports to the General Counsel, spearheads the Company's efforts with respect to information security strategy, governance, risk and incident mana” · word for word
Regulatory and compliance risk is actively managed, but remains a key focus area.
“The Company also has a Chief Compliance Officer who oversees the Regulatory Compliance Department, which is charged with tracking, reviewing and interpreting state, federal and international laws and regulations relevant to the Company's business operations.” · word for word
Key person risk is mitigated by a Co-CEO structure and succession planning, but remains a consideration.
“The Board has determined that having Co-CEOs remains the most appropriate strategic leadership choice for the Company. ... The Board has also adopted a written Emergency Succession Plan for an absence event involving one or both of the Co-CEOs” · word for word
Compensation clawback policy is in place, mitigating risk of restatement-related overpayment.
“The Company has adopted a clawback policy compliant with Rule 10D-1 of the Exchange Act and Section 303A.14 of the NYSE Listed Company Manual. ... The Clawback Policy is a 'no-fault' policy and recoupment is required regardless of whether a Covered Executive contributed to the restatement.” · word for word
27 Feb 20268-K · 5.02Annual cash retainer $110,000.00; annual equity retainer $190,000.00; Audit Committee member retainer $12,500.00open
Figures in the filing · each found in the filing text
| annual cash retainer · FY2026 | $110000.00 | |
| annual equity retainer · FY2026 | $190000.00 | |
| Audit Committee member retainer · FY2026 | $12500.00 |
Risks flagged
No material risk signals; standard board governance event.
“No transactions or arrangements requiring disclosure under Item 404(a).”
25 Feb 202610-KNet Income $1.16B (+8% y/y); Book Value Per Share $74.17 (+19% y/y); Life Underwriting Margin $1.51B (+12% y/y)open
Figures in the filing · each found in the filing text
| Net Income · FY2025 | $1.16B | +8% y/y |
| Book Value Per Share · FY2025 | $74.17 | +19% y/y |
| Life Underwriting Margin · Life Insurance · FY2025 | $1.51B | +12% y/y |
| Health Underwriting Margin · Health Insurance · FY2025 | $390M | +5% y/y |
| Net Sales · FY2025 | $948M | +13% y/y |
| Life Net Sales · Life Insurance · FY2025 | $615M | +3% y/y |
Risks flagged
Excess Investment Income Pressure
“Excess investment income declined $26 million, or 16%, in 2025 when compared with 2024.” · word for word
Health Underwriting Margin Compression
“Health underwriting margin, as a percent of premium, was 26% for 2025 down from 27% in 2024.” · word for word
Medicare Supplement Claims Utilization
“The decline in underwriting margin as a percent of premium when compared to prior years is primarily attributable to increased claims utilization during the current year from Medicare Supplement.” · word for word
4 Feb 20268-K · 2.02Net operating income per diluted share $3.39 (+8% y/y); Net income per diluted share $3.29 (+9% y/y); Net operating income per diluted share (FY) $14.52 (+17% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net operating income per diluted share · Q4-2025 | $3.39 | +8% y/y |
| Net income per diluted share · Q4-2025 | $3.29 | +9% y/y |
| Net operating income per diluted share (FY) · FY2025 | $14.52 | +17% y/y |
| Net income per diluted share (FY) · FY2025 | $14.07 | +18% y/y |
| Net income as ROE · FY2025 | 20.9% | |
| Net operating income as ROE ex-AOCI · FY2025 | 16.0% | |
| Life net sales growth (American Income) · American Income Life · Q4-2025 | 10.0% | |
| Health net sales growth (Family Heritage) · Family Heritage · Q4-2025 | 15.0% | |
| Life net sales growth (Direct to Consumer) · Direct to Consumer · Q4-2025 | 24.0% | |
| Health net sales (United American) · United American · Q4-2025 | $77M | +157% y/y |
Risks flagged
Legal proceedings expense remains a drag on net income.
“Legal proceedings reconciling item of $(0.04) per share in Q4, $(0.16) for FY.”
6 Nov 20258-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Change-of-control vesting provisions may indicate potential M&A preparedness
“Provides that if a participant in the SERP is in the Company's Executive Severance Plan and the participant's employment is terminated due to a 'Qualifying Termination' during a 'Change of Control Protection Period'... the participant will be deemed vested and eligible for Retirement Income under the SERP” · word for word
5 Nov 202510-QGlobe Life reported strong Q3 2025 results with total premium up 5%, net income up 10%, and life underwriting margin expanding 400 bps.earningsopen
Figures in the filing · each found in the filing text
| Total premium · 9M-2025 | $3.60B | +5% y/y |
| Total net sales · 9M-2025 | $661M | +6% y/y |
| Life net sales · Life · 9M-2025 | $454M | +1% y/y |
| Health net sales · Health · 9M-2025 | $207M | +21% y/y |
| Life underwriting margin · Life · 9M-2025 | $1.16B | +14% y/y |
| Health underwriting margin · Health · 9M-2025 | $291M | +4% y/y |
| Excess investment income · Investment · 9M-2025 | $108M | -15% y/y |
| Net income · 9M-2025 | $895M | +10% y/y |
| Book value per share · 2025-09-30 | $69.52 | +27% y/y |
| Net operating income per share · 9M-2025 | $11.13 | +21% y/y |
Risks flagged
Excess investment income decline
“Excess investment income declined 15% during the first nine months of 2025 to $108 million from $126 million in 2024.”
Health underwriting margin pressure
“Health underwriting margin, as a percent of premium, was 26% for 2025 down from 27% in 2024.” · word for word
Commercial mortgage loan yield decline
“The earned yield on the Company's commercial mortgage loans for the nine months ended September 30, 2025 was 6.11% compared with 8.47% in the prior year period.” · word for word
Globe Life Inc. — questions
- What did Globe Life Inc. file recently?
- 14 SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Globe Life Q3 2026 net operating income $4.84/sh vs $4.81/sh prior; net income $4.62/sh vs $4.73/sh; total premium revenue +7% YoY; 1.1M shares repurchased for $185M; FY26 guidance adjusted to $15.35-$15.65 from prior range due to one-time
Every figure on this page comes from Globe Life Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.